Vaccines Sponsors 2013
- BioOutsource
BioOutsource is the world’s fastest growing provider of contract testing services to the biotechnology industry. Our comprehensive range of biosafety testing services is supported by our highly experienced management team, derived from the former senior management of Q-One Biotech. As a result, we possess an unrivalled combination of commercial, regulatory and technical knowledge.
- Dynavax Technologies
Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company that discovers and develops novel products to prevent and treat infectious and inflammatory diseases. Our clinical-stage product candidates include:
Phase 3 HEPLISAV ™ Hepatitis B Vaccine
Phase 1 TLR Inhibitor for Lupus
Phase 1 Asthma Therapy - Immune Targeting Systems
Immune targeting Systems, Ltd has developed a powerful platform for the generation of T-cell vaccines to highly mutated viruses and to cancers. Since 2007, the company has raised £14.5m to date which is supported by prominent life science investors. The company contains proven entrepreneurs, innovators, R&D professionals and supporting team who are all highly motivated to progress our development programmes through to key clinical and company milestones. The company has completed two positive Phase I and one Phase IIa clinical trials of its lead product Flunisyn™ vaccine. Flunisyn™ stimulates the production of T-cells that recognise and destroy influenza-infected cells, and is applicable to multiple influenza strains. Recently the Company has been awarded two grants to advance the development of two other product candidates in the pipeline: a therapeutic Hepatitis B vaccine for chronic hepatitis B and a cancer vaccine for the solid tumours.
